drugset / Trial / NCT07505004
Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2)
Timeline
- Start
- 2026-01-29
- Primary completion
- 2027-01
- Completion
- 2027-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vormatrigine | Small molecule | 20 mg | Oral |
| Subject | Vormatrigine | Small molecule | 30 mg | Oral |
| Subject | Vormatrigine | Small molecule | 40 mg | Oral |